A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis.

Trial Profile

A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs Teplizumab; Teplizumab
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Actual patients number is 1 as reported by ClinicalTrials.gov.
    • 24 Aug 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top